{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:35:55Z","timestamp":1774870555344,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.ctrv.2012.03.011","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T14:44:17Z","timestamp":1335365057000},"page":"51-59","source":"Crossref","is-referenced-by-count":18,"title":["The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: A review of the literature and new perspectives"],"prefix":"10.1016","volume":"39","author":[{"given":"Jean","family":"Yared","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2012.03.011_b0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2012.03.011_b0010","unstructured":"Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues; 2008."},{"issue":"7","key":"10.1016\/j.ctrv.2012.03.011_b0015","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-hodgkin\u2019s lymphoma classification project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"issue":"7-8","key":"10.1016\/j.ctrv.2012.03.011_b0020","first-page":"396","article-title":"Phenotypic analysis of peripheral T cell lymphoma among the Japanese","volume":"43","author":"Nakamura","year":"1993","journal-title":"Acta Pathol Jpn"},{"issue":"25","key":"10.1016\/j.ctrv.2012.03.011_b0025","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-cell lymphoma project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2012.03.011_b0030","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2012.03.011_b0035","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"10.1016\/j.ctrv.2012.03.011_b0040","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the german high-grade non-hodgkin lymphoma study group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2012.03.011_b0045","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019etudes des lymphomes de l\u2019adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2012.03.011_b0050","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1200\/JCO.1989.7.12.1783","article-title":"Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin\u2019s lymphoma","volume":"7","author":"Armitage","year":"1989","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2012.03.011_b0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (groupe d\u2019etude des lymphomes agressives)","volume":"1","author":"Coiffier","year":"1990","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2012.03.011_b0060","first-page":"3452","article-title":"Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis","volume":"110","author":"AbouYabis","year":"2007","journal-title":"ASH Ann Meeting Abstr"},{"issue":"2","key":"10.1016\/j.ctrv.2012.03.011_b0065","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood.V72.2.436.436","article-title":"The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype","volume":"72","author":"Lippman","year":"1988","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2012.03.011_b0070","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ctrv.2012.03.011_b0075","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2006-04-017632","article-title":"Prognostic significance of Epstein\u2013Barr virus in nodal peripheral T-cell lymphoma, unspecified: A groupe d\u2019etude des lymphomes de l\u2019adulte (GELA) study","volume":"108","author":"Dupuis","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2012.03.011_b0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/path.945","article-title":"P53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome","volume":"195","author":"Pescarmona","year":"2001","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2012.03.011_b0085","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/path.1346","article-title":"BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation","volume":"200","author":"Rassidakis","year":"2003","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2012.03.011_b0090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood.V76.2.424.424","article-title":"Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin\u2019s lymphomas","volume":"76","author":"Vose","year":"1990","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ctrv.2012.03.011_b0095","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin\u2019s lymphoma: final analysis of the prospective LNH87-2 protocol \u2013 a groupe d\u2019etude des lymphomes de l\u2019adulte study","volume":"18","author":"Haioun","year":"2000","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2012.03.011_b0100","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.2002.20.5.1426","article-title":"Impact of high-dose chemotherapy on peripheral T-cell lymphomas","volume":"20","author":"Mounier","year":"2002","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2012.03.011_b0105","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","article-title":"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma","volume":"20","author":"Gisselbrecht","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2012.03.011_b0110","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/annonc\/mdh471","article-title":"All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the groupe d\u2019etude des lymphomes de l\u2019adulte (GELA)","volume":"15","author":"Mounier","year":"2004","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2012.03.011_b0115","first-page":"331","article-title":"High-dose chemotherapy and autologuos stem cell transplantation in previously untreated peripheral T-cell lymphoma \u2013 final analysis of a large prospective multicenter study (NLG-T-01)","volume":"118","author":"d\u2019Amore","year":"2011","journal-title":"ASH Ann Meeting Abstr"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2012.03.011_b0120","first-page":"437","volume":"94","author":"d\u2019Amore","year":"2009","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.ctrv.2012.03.011_b0125","first-page":"3566","article-title":"Favorable outcome in ALK-negative anaplastic large-cell lymphoma following intensive induction chemotherapy and autologous stem cell transplantation (ASCT): a prospective study by the Nordic lymphoma group (NLG-T-01)","volume":"116","author":"Relander","year":"2010","journal-title":"ASH Ann Meeting Abstr"},{"issue":"21","key":"10.1016\/j.ctrv.2012.03.011_b0130","first-page":"3565","article-title":"Intensive induction chemotherapy followed by autologous stem cell transplantation (ASCT) in patients with enteropathy-associated T-cell lymphoma: a prospective study by the Nordic lymphoma group (NLG-T-01)","volume":"116","author":"Jantunen","year":"2010","journal-title":"ASH Ann Meeting Abstr"},{"issue":"1","key":"10.1016\/j.ctrv.2012.03.011_b0135","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2012.03.011_b0140","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.ctrv.2012.03.011_b0145","first-page":"4477","article-title":"Frontline autologous stem cell transplantation as intensive consolidation in patients with peripheral T cell lymphomas: multicenter phase II trial in Korea","volume":"118","author":"Ahn","year":"2011","journal-title":"ASH Ann Meeting Abstr"},{"issue":"5","key":"10.1016\/j.ctrv.2012.03.011_b0150","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2012.03.011_b0155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"\u2018Grupo Espanol de Linfomas\/Trasplante Autologo de Medula Osea\u2019 (GEL-TAMO). Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the GEL-TAMO study group","volume":"79","author":"Rodriguez","year":"2007","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.ctrv.2012.03.011_b0160","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.11173","article-title":"The adjusted international prognostic index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing\/refractory peripheral T-cell lymphoma","volume":"92","author":"Rodriguez","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ctrv.2012.03.011_b0165","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish lymphoma and autologous transplantation group experience","volume":"18","author":"Rodriguez","year":"2007","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2012.03.011_b0170","first-page":"774","article-title":"Patients with mature T-cell lymphoma show high relapse rates after high dose therapy and autologous stem cell transplantation","volume":"112","author":"Nickelsen","year":"2008","journal-title":"Blood (ASH Annl Meeting Abstr)"},{"issue":"2","key":"10.1016\/j.ctrv.2012.03.011_b0175","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome-lymphoma working party of the European group for blood and marrow transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl. 15","key":"10.1016\/j.ctrv.2012.03.011_b0180","first-page":"6565","article-title":"Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for noncutaneous T-cell lymphoma (TCL): the university of texas M. D. Anderson cancer center (MDACC) experience","volume":"29","author":"Beitinjaneh","year":"2011","journal-title":"ASCO Meeting Abstr"},{"issue":"12","key":"10.1016\/j.ctrv.2012.03.011_b0185","first-page":"1372","article-title":"High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience","volume":"88","author":"Rodriguez","year":"2003","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.ctrv.2012.03.011_b0190","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodriguez","year":"2003","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2012.03.011_b0195","first-page":"96","article-title":"Survival of peripheral T-cell lymphomas (PTCLs) patients following relapse: spectrum of disease and rare long-term survivors","volume":"118","author":"Mak","year":"2011","journal-title":"ASH Ann Meeting Abstr"},{"issue":"10","key":"10.1016\/j.ctrv.2012.03.011_b0425","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.bbmt.2011.02.008","article-title":"High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors","volume":"17","author":"Nademanee","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2012.03.011_b0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5507\/bp.2011.009","article-title":"Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation","volume":"155","author":"Prochazka","year":"2011","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"7","key":"10.1016\/j.ctrv.2012.03.011_b0210","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3109\/10428194.2011.569038","article-title":"Multicenter study of comparative outcomes of hematopoietic stem cell transplant for peripheral T cell lymphoma and natural killer\/T-cell lymphoma","volume":"52","author":"Hwang","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.ctrv.2012.03.011_b0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bmt.2009.165","article-title":"Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group","volume":"45","author":"Numata","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2012.03.011_b0220","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","volume":"15","author":"Yang","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.ctrv.2012.03.011_b0225","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.ctrv.2012.03.011_b0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bmt.1705712","article-title":"Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen","volume":"40","author":"Smith","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.ctrv.2012.03.011_b0235","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.ctrv.2012.03.011_b0240","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-007-0254-1","article-title":"High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival","volume":"86","author":"Kim","year":"2007","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.ctrv.2012.03.011_b0245","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.ctrv.2012.03.011_b0250","first-page":"5110","article-title":"Late relapses characterize autologous transplantation (ASCT) in first complete remission (CR) for peripheral T-cell lymphoma (PTCL)","volume":"110","author":"Kewalramani","year":"2007","journal-title":"Blood (ASH Ann Meeting Abstr)"},{"issue":"11","key":"10.1016\/j.ctrv.2012.03.011_b0255","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/10428190412331272749","article-title":"Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant","volume":"45","author":"Jagasia","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.ctrv.2012.03.011_b0260","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bmt.1704392","article-title":"High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma","volume":"33","author":"Zamkoff","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.ctrv.2012.03.011_b0265","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","article-title":"Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey","volume":"33","author":"Jantunen","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.ctrv.2012.03.011_b0270","first-page":"1272","article-title":"Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig","year":"2003","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ctrv.2012.03.011_b0275","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.ctrv.2012.03.011_b0280","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2001.19.17.3766","article-title":"Impact of high-dose chemotherapy on peripheral T-cell lymphomas","volume":"19","author":"Rodriguez","year":"2001","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2012.03.011_b0285","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","article-title":"High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas","volume":"27","author":"Blystad","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.ctrv.2012.03.011_b0290","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1701596","article-title":"Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European group for blood and marrow transplantation (EBMT)","volume":"23","author":"Fanin","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.ctrv.2012.03.011_b0295","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ctrv.2012.03.011_b0300","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2012.03.011_b0305","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2012.03.011_b0310","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ctrv.2012.03.011_b0315","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00277-007-0423-2","article-title":"Vinorelbine and gemcitabine as salvage treatment in advanced and very poor prognosis non-Hodgkin\u2019s lymphoma patients","volume":"87","author":"Perrotti","year":"2008","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2012.03.011_b0320","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-005-0136-y","article-title":"CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas","volume":"58","author":"Kim","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"21","key":"10.1016\/j.ctrv.2012.03.011_b0325","first-page":"2829","article-title":"Gemcitabine, ifosfamide, oxaliplatin (GIFOX) as first-line treatment in high-risk peripheral T-Cell\/NK lymphomas: a phase II trial","volume":"116","author":"Corazzelli","year":"2010","journal-title":"ASH Ann Meeting Abstr"},{"issue":"Suppl. 4","key":"10.1016\/j.ctrv.2012.03.011_b0330","article-title":"Preliminary results from an open-label, multicentric, phase 2 study of Bendamustine in relapsed or refractory T-cell lymphoma from the French GOELAMS group: the BENTLY trial","volume":"22","author":"Damaj","year":"2011","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2012.03.011_b0335","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2012.03.011_b0340","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ctrv.2012.03.011_b0345","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2012.03.011_b0350","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","article-title":"A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies","volume":"111","author":"Bartlett","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ctrv.2012.03.011_b0355","first-page":"961","article-title":"Complete remissions with Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"116","author":"Shustov","year":"2010","journal-title":"ASH Ann Meeting Abstr"},{"issue":"8","key":"10.1016\/j.ctrv.2012.03.011_b0360","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of Alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2012.03.011_b0365","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified Alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2012.03.011_b0370","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.ctrv.2012.03.011_b0375","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdn726","article-title":"Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study","volume":"20","author":"Kim","year":"2009","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2012.03.011_b0380","first-page":"4110","article-title":"First interim safety analysis of a phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without Alemtuzumab and consolidated by autologous hematopoietic stem cell transplant","volume":"118","author":"d\u2019Amore","year":"2011","journal-title":"ASH Ann Meeting Abstr"},{"issue":"22","key":"10.1016\/j.ctrv.2012.03.011_b0385","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2012.03.011_b0390","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2012.03.011_b0395","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2012.03.011_b0400","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2011.573031","article-title":"Lenalidomide monotherapy for relapsed\/refractory peripheral T-cell lymphoma not otherwise specified","volume":"52","author":"Zinzani","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.ctrv.2012.03.011_b0405","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/annonc\/mdn431","article-title":"Phase I study of proteasome inhibitor Bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK\/T-cell lymphoma","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2012.03.011_b0410","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor Bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies","volume":"16","author":"Marchi","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2012.03.011_b0415","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"issue":"Suppl. 15","key":"10.1016\/j.ctrv.2012.03.011_b0420","first-page":"8045","article-title":"Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial","volume":"28","author":"Foss","year":"2010","journal-title":"ASCO Meeting Abstr"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T17:03:23Z","timestamp":1594055003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737212000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0305737212000771"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.03.011","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}